For research use only.
CAS No. 50-24-8
Prednisolone (NSC-9900) is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.
Selleck's Prednisolone (NSC-9900) has been cited by 11 publications
2 Customer Reviews
Combinations of EPZ-6438 with Prednisolone or Dexamethasone in DOHH2 EZH2 wild-type GCB lymphoma cell lines. All dose response plots were generated in Graphpad Prism and curves fitted to a four-parameter model with variable slope (2 biological replicates). Doses of EPZ-6438 ranged from 15.6-1000 nM, doses of Prednisolone ranged from 7.8–1000 nM, and doses of Dexamethasone ranged from
0.8-100 nM. The potency of Prednisolone is increased with addition of EPZ-6438 in DOHH2 cells.
PLoS One, 2014, 9(12):e111840.. Prednisolone (NSC-9900) purchased from Selleck.
Inhibition of proliferation of CMV-specifi CD8+ T cells by everolimus. Isolated CD8+ T cells were labeled with CFSE and stimulated with CMVpp65 peptide in a MLPC in the presence of increasing doses of everolimus. After 6 days T cells were stained for CD8 expression and specifi city for the HLA-A2 restricted epitope pp65 (495-503) . The numbers show percentages of (B) tetramer-positive cells of total CD8+ T cells using fl ow cytometry. One representative histogram/dot blot out of six experiments is shown.
Leuk Lymphoma, 2014, 55(5):1144-50. . Prednisolone (NSC-9900) purchased from Selleck.
Purity & Quality Control
Choose Selective Glucocorticoid Receptor Inhibitors
|Description||Prednisolone (NSC-9900) is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.|
Prednisolone (50 mg/kg, im) given 15 min before LPS-attenuated production of NO2- and NO3- by neutrophils and suppresses LPS-stimulated mRNA for NOS II in rat neutrophils.  Prednisolone reduces joint swelling through a mechanism associated with a reduction in IL-1beta and IL-6 protein and mRNA expression levels in SCW-induced arthritis rats.  Prednisolone's anti-inflammatory effects can be mediated by reducing cellular adhesion molecule (CAM) expression. Prednisolone (0.75 mg/kg) reduces macrophages (-59%, -57%), CD4(+) T-cells (-50%, -60%), CD8(+) T-cells (-58%, -48%), and eosinophils (-36%, -25%) in quadriceps and soleus muscles, respectively. Prednisolone-treated mice also exhibits decreased vascular P-selectin (-82%) and ICAM-1 (-52%) expression and fewer L-selectin (-79%) and ICAM-1 (-57%) expressing mononuclear cells in quadriceps. Prednisolone reduces sarcolemmal damage and degeneration as well in Dystrophin-deficient, mdx mice. 
|In vivo||Prednisolone (5 mg/kg) causes alterations in diaphragmatic contractile properties and histological changes without fiber atrophy in rats. Prednisolone results in an increased number of diaphragmatic bundles in rats.  Prednisolone induces a significant decline of PL-pO2, while CoBF, CMs, CAPs, and ABRs revealed no change in guinea pigs. |
-  Kolls J, et al. Proc Soc Exp Biol Med, 1994, 205(3), 220-229.
-  Rioja I, et al. Clin Exp Immunol, 2004, 137(1), 65-73.
-  Bauer A, et al. J Cardiovasc Pharmacol, 2002, 39(3), 460-467.
|In vitro||DMSO||72 mg/mL (199.75 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04874610||Recruiting||Drug: Methylprednisolone||Pediatric Obesity|Asthma in Children||Duke University||August 16 2021||--|
|NCT04965636||Not yet recruiting||Drug: Mepolizumab||Hypereosinophilic Syndrome||GlaxoSmithKline||August 31 2021||Phase 3|
|NCT05001737||Not yet recruiting||Drug: Emapalumab||Macrophage Activation Syndrome|Secondary Hemophagocytic Lymphohistiocytosis|Still Disease|Systemic Lupus Erythematosus||Swedish Orphan Biovitrum||August 10 2021||Phase 3|
|NCT05006703||Recruiting||Behavioral: Breathe4T||Adolescent Behavior|Asthma||University of Southampton|University of Bath|Aston University|University Hospital Southampton NHS Foundation Trust|Asthma UK||June 22 2021||Not Applicable|
|NCT04797325||Not yet recruiting||Drug: Vedolizumab|Drug: Prednisolone||Immune-Mediated Colitis||University of Copenhagen||April 2021||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.